论文部分内容阅读
目的:观察EPO对慢性充血性心力衰竭(CHF)治疗效果。方法:选择CHF患者212例,随机分为非EPO治疗组(56例)和EPO治疗组(156例)。其中非EPO治疗组采用常规抗心衰治疗,EPO治疗组接受常规抗心衰治疗和EPO治疗,直至临床观察结束。治疗后观察心功能指标改变。结果:156例心衰患者经过EPO治疗后,左室射血分数,每搏输出量,每分输出量,心指数均较非EPO治疗对照组患者明显改善(P<0.05),其中尤以左室射血分数改善最为明显(P<0.01)。156例EPO治疗组患者中116例心衰伴贫血患者心功能各项指标的改善较40例心衰不伴贫血患者更为明显,具有显著统计学意义(P<0.01)。结论:EPO对CHF患者心功能的改善主要是因为EPO的促红细胞生成作用。EPO对于慢性心功能不全有独立于促红细胞生成以外的治疗作用。
Objective: To observe the effect of EPO on chronic congestive heart failure (CHF). Methods: 212 CHF patients were randomly divided into non-EPO treatment group (56 cases) and EPO treatment group (156 cases). Among the non-EPO treatment groups, conventional anti-heart failure treatment was used, EPO treatment group received conventional anti-heart failure treatment and EPO treatment until the end of clinical observation. Observation of cardiac function after treatment changes. Results: After EPO treatment, the left ventricular ejection fraction, stroke volume, output per minute and cardiac index in 156 patients with heart failure were significantly better than those in the non-EPO-treated control group (P <0.05), especially left Room ejection fraction was the most obvious improvement (P <0.01). The improvement of cardiac function in 116 patients with heart failure and anemia in 156 patients with EPO was more obvious than those with 40 patients without heart failure (P <0.01). Conclusion: The improvement of cardiac function in patients with CHF due to EPO is mainly due to the erythropoietic effect of EPO. EPO has a therapeutic effect independent of erythropoiesis in chronic heart failure.